

UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

MANAGEMENT'S RESPONSIBILITY

To the Shareholders of Planet 13 Holdings Inc.:

Management is responsible for the preparation and presentation of the accompanying unaudited condensed interim consolidated financial statements, including responsibility for significant accounting judgments and estimates in accordance with International Financial Reporting Standards. This responsibility includes selecting appropriate accounting principles and methods, and making decisions affecting the measurement of transactions in which objective judgment is required.

In discharging its responsibilities for the integrity and fairness of the unaudited condensed interim consolidated financial statements, management designs and maintains the necessary accounting systems and related internal controls to provide reasonable assurance that transactions are authorized, assets are safeguarded, and financial records are properly maintained to provide reliable information for the preparation of unaudited condensed interim consolidated financial statements.

The Board of Directors and the Audit Committee are composed primarily of directors who are neither management nor employees of the Company. The Board is responsible for overseeing management in the performance of its financial reporting responsibilities, and for approving the financial information presented. The Board fulfils these responsibilities by reviewing the financial information prepared by management and discussing relevant matters with management and the external auditors. The Audit Committee has the responsibility of meeting with management and the external auditors to discuss the internal controls over the financial reporting process, auditing matters and financial reporting issues. The Audit Committee is also responsible for recommending the appointment of the Company's external auditors.

The unaudited condensed interim consolidated financial statements were approved by the Board of Directors on November 23, 2021, and were signed on behalf of Management by:

"Larry Scheffler"	"Robert Groesbeck"
Larry Scheffler, Co-CEO	Robert Groesbeck, Co-CEO
"Dennis Logan"	
Dennis Logan, CFO	

Unaudited condensed Interim Consolidated Statements of Financial Position

Expressed in United States Dollars	As at	As at			
•	September 30,	December	December 31,		
	2021	2020			
Assets					
Current Assets					
Cash	\$ 73,694,308	\$ 79,00	00,850		
Restricted cash (Note 8)	55,000,000		-		
HST receivable	49,144	10	03,445		
Inventories (Note 5)	12,312,316	7,33	34,717		
Biological assets (Note 6)	1,340,731	64	10,995		
Prepaid expenses and other current assets (Note 10)	7,196,266	2,63	37,547		
Total Current Assets	149,592,765	89,71	17,554		
Proporty and equipment (Note 7)	12 506 759	32.07	72 025		
Property and equipment (Note 7)	42,506,758		73,925		
Licenses (Note 8)	7,265,422		07,362		
Right of use assets (Note 9)	20,082,635		19,721		
Long-term deposits and other assets	1,066,819		54,443		
T . 1	70,921,634		35,451		
Total Assets	\$ 220,514,399	\$ 150,00	03,005		
Liabilities					
Current Liabilities					
Accounts payable	\$ 4,137,182	\$ 1,68	33,833		
Accrued expenses	6,821,741		14,714		
Income taxes payable	-	1,22	20,652		
Notes payable - current portion (Note 11)	884,000	88	34,000		
Long -term lease liabilities current portion (Note 12)	86,700		-		
Total Current Liabilities	11,929,623	6,63	33,199		
Long -term lease liabilities net of current portion (Note 12)	23,184,972	22.33	26,077		
Other long-term liabilities	28,000		28,000		
Deferred tax liability	249,875		13,422		
Deferred tax hability	23,462,847		57,499		
Total Liabilities	35,392,470		00,698		
Shareholders' Equity					
Share capital (Note 13)	201,198,984		-		
Restricted share units (Note 13)	13,571,835		52,351		
Warrants (Note 13)	11,486,105		72,053		
Option reserve (Note 13)	201,364		76,081		
Accumulated other comprehensive loss	(430,148	,	79,122)		
Deficit	(40,906,211		06,090)		
Total Shareholders' Equity	185,121,929	120,70	02,307		
Total Liabilities and Shareholders' Equity	\$ 220,514,399	\$ 150,00	3,005		

Nature of operations (Note 1) Commitment and Contingencies (Note 15) Subsequent event (Note 20)

The unaudited condensed interim consolidated financial statements were approved by the Board of Directors and were signed on its behalf by:



UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

Expressed in United States Dollars		Three months Ended September 30, 2021		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Ended September 30,		Three months Ended September 30, 2020		Nine months Ended September 30, 2021		Nine months Ended September 30, 2020	
Revenue							-																																										
Revenues, net of discounts	\$	32,952,254	\$	22,797,338	\$	89,612,050	\$	50,351,336																																									
Cost of Goods Sold (Note 5)		(15,335,731)		(9,821,561)		(40,491,286)		(23,620,446)																																									
Gross Profit before fair value asset adjustment		17,616,523		12,975,777		49,120,764		26,730,890																																									
Realized fair value amounts included in inventory sold		(427,220)		(961,235)		(668,644)		(1,482,428)																																									
Unrealized fair value gain on growth of biological assets		355,213		457,166		590,991		1,257,134																																									
Gross Profit		17,544,516		12,471,708		49,043,111		26,505,596																																									
Expenses																																																	
General and Administrative (Note 14)		13,111,649		6,198,121		31,812,266		17,280,258																																									
Sales and Marketing		1,959,579		991,215		4,162,934		2,684,176																																									
Depreciation and Amortization (Note 7 & 9)		1,721,193		1,076,774		3,901,212		3,103,847																																									
Share-Based Compensation Expense (Note 13 and Note 17)		6,613,846		569,227		12,211,567		2,006,067																																									
Total Expenses		23,406,267		8,835,337		52,087,979		25,074,348																																									
Income From Operations		(5,861,751)		3,636,371		(3,044,868)		1,431,248																																									
Other Expense:																																																	
Interest expense, net		503,808		438,687		1,456,249		1,291,949																																									
Realized foreign exchange gain		(1,621,267)		-		(1,766,823)		-																																									
Other income		(152,466)		(174,145)		(338,890)		(250,204)																																									
Total Other Expense (Income)		(1,269,925)		264,542		(649,464)		1,041,745																																									
Income before income taxes		(4,591,826)		3,371,829		(2,395,404)		389,503																																									
Provision for tax - current		3,938,824		2,620,603		10,144,755		5,340,695																																									
Provision for tax - deferred		(106,611)		390,277		(140,038)		85,016																																									
Income (loss) for the period	\$	(8,424,039)	\$	360,949	\$	(12,400,121)	\$	(5,036,208)																																									
Other Comprehensive Income																																																	
Foreign exchange translation gain		(1,751,017)		(152,313)		48,974		(204,943)																																									
Net Comprehensive Income (Loss) for the period	\$	(10,175,056)	\$	208,636	\$	(12,351,147)	\$	(5,241,151)																																									
Net income (loss) per share for the period																																																	
Basic and diluted income (loss) per share (Note 16)	\$	(0.04)	\$		\$	(0.06)	\$	(0.03)																																									
Weighted Average Number of Common Shares Outstanding																																																	
Basic and diluted		196,357,392		162,536,424		194,529,766		144,932,087																																									

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

Expressed in United States Dollars							Accumulated		
	Number of	Common	Class A				Other		
	shares	Share	Restricted	Restricted Share		Option	Comprehensive	Accumulated	Total
	outstanding	Capital	Shares	Units	Warrants	Reserve	Income (Loss)	Deficit	Equity
Balance at January 1, 2020	137,660,559 \$	46,367,730 \$	5,619,119 \$	4,119,485 \$	5,961,091 \$	399,439 \$	(607,707) \$	(20,564,565) \$	41,294,592
Shares issued on acquisition	3,940,932	-	4,453,831	-	-	-	-	-	4,453,831
Shares issued on acquisition	1,374,833	2,918,277	-	-	-	-	-	-	2,918,277
Shares issued on exercise of RSUs	2,685,344	3,313,152	-	(3,313,152)	-	-	-	-	-
Share based compensation - RSUs	-	-	-	1,954,834	-	-	-	-	1,954,834
Shares issued on exercise of warrants	12,320,368	20,109,919	-	-	(3,324,795)	-	-	-	16,785,124
Shares issued on exercise of options	233,001	295,690	-	-	-	(139,271)	-	-	156,419
Share based compensation - options	-	-	-	-	-	51,233	-	-	51,233
Shares issued on bought deal financings - net	11,580,500	18,690,129	-	-	5,117,522	-	-	-	23,807,651
Cumulative foreign exchange loss	-	-	-	-	-	-	(204,943)	-	(204,943)
Net loss for the period	-	-	-	-	-	-	-	(5,036,208)	(5,036,208)
Balance September 30, 2020	169,795,537	91,694,897	10,072,950	2,761,167	7,753,818	311,401	(812,650)	(25,600,773)	86,180,810
Shares issued on conversion from Restricted Shares to Common	-	4,453,831	(4,453,831)	-	-	-	-	-	-
Share based compensation - RSUs	-	-	-	501,184	-	-	-	-	501,184
Shares issued on exercise of warrants	5,211,903	20,932,258	-	-	(5,063,933)	-	-	-	15,868,325
Shares issued on exercise of options	100,000	102,208	-	-	-	(40,637)	-	-	61,571
Share based compensation - options	-	-	-	-	-	5,317	-	-	5,317
Shares issued on bought deal financings - net	6,698,750	16,374,721	-	-	4,282,168	-	-	-	20,656,889
Cumulative foreign exchange gain	-	-	-	-	-	-	333,528	-	333,528
Net loss for the period	-	-	-	-	-	-	-	(2,905,317)	(2,905,317)
Balance December 31, 2020	181,806,190	133,557,915	5,619,119	3,262,351	6,972,053	276,081	(479,122)	(28,506,090)	120,702,307
Balance at January 1, 2021	181,806,190 \$	133,557,915 \$	5,619,119 \$	3,262,351 \$	6,972,053 \$	276,081 \$	(479,122) \$	(28,506,090) \$	120,702,307
Shares issued on conversion from Restricted Shares to Common	-	5,619,119	(5,619,119)	-	-	-	-	-	-
Shares issued on exercise of RSUs	915,803	1,898,979	-	(1,898,979)	-	-	-	-	-
Share based compensation - RSUs	-	-	-	12,208,463	-	-	-	-	12,208,463
Shares issued on exercise of warrants	3,758,940	17,841,047	-	-	(3,761,366)	-	-	-	14,079,681
Share issuance on exercise of options	121,336	164,037	-	-	-	(77,821)	-	-	86,216
Share based compensation - options	-	-	-	-	-	3,104	-	-	3,104
Shares issued on bought deal financings - net	9,861,250	42,117,887	-	-	8,275,418	-	-	-	50,393,305
Cumulative foreign exchange gain	-	-	-	-	-	-	48,974	-	48,974
Net loss for the period	-	-	-	-	-	-	_	(12,400,121)	(12,400,121)
Balance September 30, 2021	196,463,519 \$	201,198,984	- S	13,571,835 \$	11,486,105 \$	201,364 \$	(430,148) \$	(40,906,211) \$	185,121,929

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

Expressed in United States Dollars	Nine Months Ended September 30, 2021	Nine Months Ended September 30, 2020		
Operating activities				
Net loss for the period	\$ (12,400,121)	\$ (5,036,208)		
Add (deduct) non-cash items:				
Share based compensation (Note 13 and 17)	12,211,567	2,006,067		
Depreciation and amortization (Note 7 and 9)	5,652,167	4,451,334		
Deferred tax liability	(63,547)	87,821		
Other assets	(12,376)	-		
Non-cash accretion of lease liabilities (Note 12)	227,883	-		
Non-cash interest expense on ROU Liabilities (Note 12)	2,310,243	1,769,500		
Net change in non-cash working capital				
HST receivable	53,260	(47,316)		
Inventories (Note 5)	(4,977,599)	(2,247,582)		
Biological assets (Note 6)	(699,736)	(855,564)		
Prepaid expenses and other assets (Note 10)	(4,553,877)	1,540,938		
Long term deposits and other assets	<u>-</u>	(336,751)		
Accounts payable	1,677,254	1,231,431		
Accrued expenses	3,977,027	1,116,045		
Income tax payable	(1,220,652)	5,340,695		
Cash flow provided by operating activities	2,181,493	9,020,410		
Investing activities				
Purchase of property and equipment (Note 7)	(14,366,413)	(3,101,240)		
Restricted cash (Note 8 and Note 20)	(55,000,000)	(5,101,2.0)		
Purchase of licenses (Note 8)	(258,060)	(1,053,353)		
Cash flow used in investing activities	(69,624,473)	(4,154,593)		
Financing activities				
Issuance of shares on warrant and option exercises (Note 13)	14,165,897	16,941,543		
Issuance of shares and warrants on financings (Note 13)	50,393,305	23,807,651		
Payment on lease liabilities (Note 12)	(2,469,078)	(1,463,920)		
Cash flow provided by financing activities	62,090,124	39,285,274		
Net increase in cash	(5,352,856)	44,151,091		
Cash at beginning of the period	79,000,850	12,814,712		
Effect of foreign exchange on cash	46,314	(204,943)		
Cash at end of the period	\$ 73,694,308	\$ 56,760,860		
Cash at the of the period	g 73,074,300	Ψ 30,700,000		

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

Expressed in United States Dollars	Nine Months Ended September 30, 2021	Nine Months Ended September 30, 2020		
Supplemental Disclosure of Cash Flow Cash paid during the period for: Interest on ROU liabilities Income taxes	\$ 2,561,190 \$ 11,631,307	\$ \$	1,736,350	
Non-cash activities Carrying value of warrants exercised	\$ 3,761,366	\$	3,324,795	
Carrying value of RSUs exercised	\$ 1,898,979	\$	3,354,962	
Carrying value of options exercised	\$ 77,821	\$	139,271	
Licenses and intangible assets	\$ -	\$	5,161,720	
Construction in progress in accounts payable	\$ 774,954	\$	-	
Lease liabilities	\$ 876,547	\$	9,609,048	

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

1) Nature of operations

Planet 13 Holdings Inc. ("P13" or the "Company") was incorporated under the Canada Business Corporations Act on April 26, 2002, and continued under the British Columbia Corporations Act on September 24, 2019. The Company is a vertically integrated cultivator and provider of cannabis and cannabis-infused products licensed under the laws of the State of Nevada, with six licenses for cultivation (three medical and three recreational), six licenses for production (three medical and three recreational), and three dispensary licenses (one medical license and two recreational licenses). In addition, the Company holds one recreational dispensary licence in the city of Santa Ana, California.

P13 is a public company which is listed on the Canadian Securities Exchange under the symbol "PLTH" and the OTCQX exchange under the symbol "PLNHF".

The Company's registered office is located at 240 Richmond Street West, Toronto, ON M5V 1V6 and the head office address is 2548 West Desert Inn. Rd, Las Vegas, NV 89109.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. The outbreak of this contagious disease, along with the related adverse public health developments, have negatively affected workforces, economies and financial markets on a global scale. The Company incurred lower revenues, and additional expenditures related to COVID-19 during the first half of 2020. During the first half of 2020 the Company's operations in Nevada were mandated as an essential service but were restricted to delivery only, with no curb-side pickup or instore sales permitted until such delivery-only order was lifted on May 30, 2020. The Company's operating results were not materially impacted during the first quarter of 2021. Currently, the Company is closely monitoring the impact of the pandemic on all aspects of its business, and it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or results of operations.

The Company is subject to risks common in the life sciences and consumer products industries including, but not limited to, compliance with government regulations, regulatory approvals, competitive markets, new technological innovations, protection of proprietary technology, dependence on key personnel, uncertainty of market acceptance and the need to obtain additional financing.

While cannabis and CBD-infused products are legal under the laws of several U.S. states (with varying restrictions applicable), the United States Federal Controlled Substances Act classifies all "marijuana" as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for use under medical supervision.

The federal government currently is prohibited by statute from prosecuting businesses that operate in compliance with applicable state and local medical cannabis laws and regulations; however, this does not protect adult use cannabis. In addition, if the federal government changes this position, it would be financially detrimental to the Company.

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") with the going concern assumption, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company's ability to realize its assets and discharge its liabilities is dependent upon the Company obtaining the necessary financing and ultimately upon its ability to achieve profitable operations. Management estimates that the Company will be able to meet its obligations and to sustain operations for at least the next twelve months.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

1) Nature of operations (continued)

Failure to arrange adequate financing on acceptable terms and/or achieve profitability may have an adverse effect on the financial position, results of operations, cash flows and prospects of the Company. These condensed interim consolidated financial statements do not give effect to adjustments to assets or liabilities that would be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

2) Statement of Compliance

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standards ("IAS") 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB") and should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2020. They do not include all the information required for a complete set of International Financial Reporting Standards ("IFRS") financial statements. However, selected explanatory notes are included to explain events and transactions deemed significant to provide an understanding of the changes in the Company's financial position and performance since its most recent annual financial statements. These unaudited condensed interim consolidated financial statements are presented in U.S. dollars. The Canadian dollar serves as the functional currency of the Parent company. The Company's subsidiaries all have the U.S. dollar as their functional currency.

The accounting policies applied in the preparation of these condensed interim consolidated financial statements are consistent with those applied and disclosed in the Company's audited consolidated financial statements for the year ended December 31, 2020.

The unaudited condensed interim consolidated financial statements were approved and authorized for issuance by the Board of Directors on November 23, 2021.

(a) Basis of Measurement

These unaudited condensed interim consolidated financial statements have been prepared on the going concern basis, under the historical cost convention except for certain financial instruments that are measured at fair value, and biological assets that are measured at fair value less costs to sell, as described herein.

(b) Principles of Consolidation

These unaudited condensed interim consolidated financial statements include the financial position, results of operations and cash flows of the Company and its subsidiaries. The Company's subsidiaries as at September 30, 2021, are as follows:

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

2) Statement of compliance (continued)

Subsidiary	Country of Incorporation	Economic Interest	Nature of Business
MM Development Company, Inc. ("MMDC")	USA	100%	Vertically
			integrated
			Cannabis
			Operations
BLC Management Company LLC. ("BLC")	USA	100%	Management
			Company
LBC CBD LLC. ("LBC")	USA	100%	CBD Retail Sales
			and Marketing
Newtonian Principles Inc.	USA	100%	Cannabis Retail
			Sales
MM Development MI, Inc.	USA	100%	Holding Company
MM Development CA, Inc.	USA	100%	Holding Company
Planet 13 Illinois, LLC	USA	49%	Holding Company
Planet 13 Florida LLC	USA	100%	Holding Company
BLC NV Food, LLC	USA	100%	Food Retailing
By The Slice, LLC	USA	100%	Food Retailing

Subsidiaries - Subsidiaries are entities over which the Company has control, whereby control is defined as the power to direct activities of an entity that significantly affect the entity's returns so as to obtain benefit from its activities. Control is presumed to exist where the Company has a shareholding of more than one half of the voting rights in its subsidiaries. The effects of potential voting rights that are currently exercisable are considered when assessing whether control exists. Subsidiaries are fully consolidated from the date control is transferred to the Company and are de-consolidated from the date at which control ceases.

All intercompany transactions between the Company and its subsidiaries are eliminated upon consolidation.

3) Significant accounting judgements, estimates and assumptions

The preparation of financial statements in conformity with IFRS requires the use of judgments and/or estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These judgments and estimates are based on management's best knowledge of the relevant facts and circumstances, having given regard to previous experience, but actual results may differ materially from the amounts included in the financial statements. The critical estimates and judgments applied in the preparation of the unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2021, are consistent with those applied and disclosed in note 4 of the Company's audited consolidated financial statements for the year ended December 31, 2020.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

4) Financial instruments and risk management

a) Fair value hierarchy

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.

The fair value of hierarchy has the following levels:

- Level 1 quoted prices in active markets for identical financial instruments.
- Level 2 quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
- Level 3 valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company's financial instruments include cash, restricted cash, accounts payable, accrued expenses and notes payable. The carrying value of cash is carried at fair value. Accounts payable and accrued expenses and notes payable approximate their fair value due to their short-term nature.

The following table summarizes the Company's financial instruments on September 30, 2021:

	Septembe	r 30,	2021	December 31, 2020		
Amortized cost	Fair Value	_ C:	arrying value	Fair Value	Carrying value	
Financial Assets:						
Cash	\$ 73,694,308	\$	73,694,308	\$ 79,000,850	\$ 79,000,850	
Restricted cash	55,000,000		55,000,000			
Total	\$ 128,694,308	\$	128,694,308	\$ 79,000,850	\$ 79,000,850	
Financial Liabilities						
Accounts Payable	\$ 4,137,182	\$	4.137.182	\$ 1.683.833	\$ 1.683.833	
Accrued expenses	6,821,741		6,821,741	2,844,714	2,844,714	
Notes payable - current	884,000		884,000	884,000	884,000	
Total	\$ 11,842,923	\$	11,842,923	\$ 5,412,547	\$ 5,412,547	

b) Credit risk

Credit risk is the risk that a third party might fail to discharge its obligations under the terms of a financial instrument. Credit risk arises from cash with banks and financial institutions. It is management's opinion that the Company is not exposed to significant credit risk arising from these financial instruments. The Company limits credit risk by entering into business arrangements with high credit-quality counterparties.

c) Interest rate risk

Interest rate risk is the risk of losses that arise as a result of changes in contracted interest rates. The Company is not exposed to significant interest rate risk, as the Company's notes payable have fixed interest rates.

d) Currency risk

The Company operates internationally and is exposed to foreign exchange risk arising from various currency exposures. The Company operates in Canada and the United States and incurs certain expenditures and obtains financing in both CAD and USD. Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

4) Financial instruments and risk management (continued)

denominated in a currency that is not the functional currency of the Company or subsidiary that holds the financial asset or liability. The Company's risk management policy is to review its exposure to non-CAD and non-USD forecasted operating costs on a case-by-case basis. The majority of the Company's forecasted operating costs are in USD and CAD. The risk is measured using sensitivity analysis and cash flow forecasting.

The carrying amount of CAD financial assets and liabilities in USD as at September 30, 2021, is as follows:

US Dollar amounts of foreign currency assets and liabilities

	Assets	Liabilities
Canadian Dollars	\$1,460,926	\$137,890

Based on the financial instruments held as at September 30, 2021, the Company's other comprehensive income would have changed by approximately \$120,276 had the US dollar shifted by 10% as a result of foreign exchange effect on translation of non-US dollar denominated financial instruments.

At September 30, 2021, the Company had no hedging agreements in place with respect to foreign exchange rates. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.

e) Liquidity risk

Prudent liquidity risk management implies maintaining at all times sufficient cash, liquid investments and committed credit facilities to meet the Company's commitments as they arise. The Company manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring forecast and actual cash flows. Where insufficient liquidity may exist, the Company may pursue various debt and equity instruments for short or long-term financing of its operations. The Company has the following contractual obligations:

As at September 30, 2021

	 <1 Year	1 to :	5 Years	The	reafter	 Total
Accounts Payable	\$ 4,137,182	\$	-	\$	-	\$ 4,137,182
Accrued expenses	\$ 6,821,741	\$	-	\$	-	\$ 6,821,741
Notes Payable	\$ 884,000	\$	-	\$	-	\$ 884,000
Lease liabilities	\$ 3,573,514	\$ 15,	397,949	\$ 47,	083,499	\$ 66,054,962

f) Pricing risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. See Note 6 for the Company's assessment of certain changes in the fair value assumption used in the calculation of biological asset values.

g) Concentration risk

The Company operates in California and Nevada. Should economic conditions deteriorate within these regions, its results of operations and financial position would be negatively impacted.

h) Banking Risk

Notwithstanding that a majority of states have legalized medical marijuana, there has been no change in US federal banking laws related to the deposit and holding of funds derived from activities related to the marijuana industry. Given that US federal law provides that the production and possession of cannabis is illegal, there is a strong argument that banks cannot accept for deposit funds from businesses involved with the marijuana industry. Consequently, businesses involved in the marijuana industry often have difficulty accessing the US banking system and traditional financing

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

4) Financial instruments and risk management (continued)

sources. The inability to open bank accounts with certain institutions may make it difficult to operate the business of the Company and leaves their cash holdings vulnerable.

i) Asset Forfeiture Risk

Because the cannabis industry remains illegal under US federal law, any property owned by participants in the cannabis industry which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property was never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture.

5) Inventories

Finished goods inventory consists of dried cannabis, concentrates, edibles and other products that are complete and available for sale (both internally generated inventory and third-party products purchased in the wholesale market). Work in process inventory consists of cannabis after harvest, in the processing stage. Packaging and miscellaneous consist of consumables for use in the transformation of biological assets and other inventory used in production of finished goods. The Company's inventories are comprised of:

	September 30, 2021	December 31, 2020
Raw Material		
Harvested Cannabis	\$ 1,171,441	\$ 1,291,905
Packaging and miscellaneous	1,348,892	566,157
Total Raw Material	2,520,333	1,858,062
Work in Process	2,975,580	2,115,752
Finished Goods	6,816,403	3,360,903
Total Inventories	\$ 12,312,316	\$ 7,334,717

During the three months ended September 30, 2021, the Company recognized \$15,335,731 (2020 - \$9,821,561) of inventory expensed to cost of goods sold. During the nine months ended September 30, 2021, the Company recognized \$40,491,286 (2020 - \$23,620,446) of inventory expensed to cost of goods sold.

6) Biological Assets

Biological assets consist of cannabis plants. The changes in the carrying value of biological assets are shown below:

	September 30, 2021			ecember 31, 2020
Beginning balance	\$	640,995	\$	514,526
Biological assets acquired		-		326,592
Production costs capitalized		5,197,747		4,733,966
Net change in fair value less costs to sell				
due to biological transformation		590,991		2,276,141
Transferred to inventory upon harvest		(5,089,002)		(7,210,230)
Ending balance	\$	1,340,731	\$	640,995

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

6) Biological Assets (continued)

The Company values its biological assets at the end of each reporting period at fair value less costs to sell. This is determined using a valuation model to estimate the expected harvest yield per plant applied to the estimated price per gram less cost to sell. This model also considers the progress in the plant life cycle.

The following significant unobservable inputs, all of which are classified as level 3 on the fair value hierarchy and are subject to volatility and several uncontrollable factors which could significantly affect the fair value of biological assets in future periods, were used by management as part of this model:

- Growth cycle the average number of weeks in the growing cycle is 110 days from propagation to harvest for both the three and nine months ended September 30, 2021, and 2020;
- Stage of growth represents the weighted average number of days out of the 110-day growing cycle that biological assets have reached as at the measurement date;
- Yield by plant represents the expected number of grams of finished cannabis inventory which are expected to be obtained from each harvested cannabis plant. The average harvest yield of whole flower used is 117 grams per plant for 2021 (2020 91 grams);
- Survival rate the estimated survival rate of cannabis plants as they move from one stage of growth to the next (from germination to vegetative to flowering) based on the Company's historical results. As plants mature at each stage, their survival rate increases;
- Price the average price used of \$5.29 per gram in 2021 (nine months ended September 30, 2020, \$4.73 per gram) derived from the average selling price of wholesale cannabis as published by the Nevada Department of Taxation for the periods presented;
- Post harvest costs calculated as the cost per gram of harvested cannabis to complete the sale of cannabis
 plants after harvest, consisting of the cost of direct and indirect materials and labor related to labelling and
 packaging.

The following quantifies each unobservable input, and also provides the impact a 10% increase/decrease in each input would have on the reported fair value of biological assets:

			10% change as at					
	September 30,	September 30,	September 30,	September 30,				
	2021	2020	2021	2020				
Stage of growth	42.20%	39.10%	\$ 144,077	\$ 134,601				
Yield by plant	117 grams	91 grams	341,340	334,000				
Survival rate	87.90%	87.10%	299,881	299,596				
Wholesale Selling price	\$5.29	\$4.73	134,104	62,576				

As at September 30, 2021, the biological assets were on average 42.2% complete (2020 - 39.1%); are expected to ultimately yield approximately 566.9kg of cannabis (2020 - 633.4kg); and the estimated fair value less costs to sell of dry cannabis was \$5.29 per gram.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

7) Property and Equipment

	I	and and	В	uildings and				Leasehold	(Construction		Total
	Land	Improvements		Structures]	Equipment	Ir	nprovements		in Progress	C	apital Assets
Cost												
At December 31, 2019	\$	625,146	\$	1,698,077	\$	4,075,085	\$	27,094,559	\$	1,778,283	\$	35,271,150
Additions		-		9,817		2,096,736		2,110,612		3,174,371		7,391,536
Transfers & disposals		-		-		65,435		1,242,871		(1,585,399)		(277,093)
At December 31, 2020		625,146		1,707,894		6,237,256		30,448,042		3,367,255		42,385,593
Additions		-		-		1,683,229		1,365,921		12,286,430		15,335,580
Transfers & disposals		-		-		1,810,355		13,606,520		(15,607,634)		(190,759)
At September 30, 2021	\$	625,146	\$	1,707,894	\$	9,730,840	\$	45,420,483	\$	46,051	\$	57,530,414
Accumulated Depreciation												
At December 31, 2019	\$	76,737	\$	161,258	\$	1,242,945	\$	3,579,056	\$	-	\$	5,059,996
Additions		51,194		42,492		1,034,935		4,141,006		-		5,269,627
Transfers & disposals		-		-		(17,955)		-		-		(17,955)
At December 31, 2020		127,931		203,750		2,259,925		7,720,062		-		10,311,668
Additions		38,396		32,023		1,014,984		3,640,177		-		4,725,580
Transfers & disposals		-		-		(1,231)		(12,361)		-		(13,592)
At September 30, 2021	\$	166,327	\$	235,773	\$	3,273,678	\$	11,347,878	\$	-	\$	15,023,656
Net book value												
At December 31, 2020	\$	497,215	\$	1,504,144	\$	3,977,331	\$	22,727,980	\$	3,367,255	\$	32,073,925
At September 30, 2021	\$	458,819	\$	1,472,121	\$	6,457,162	\$	34,072,605	\$	46,051	\$	42,506,758

As of September 30, 2021, costs related to the construction of facilities were capitalized as construction in progress and not depreciated. Depreciation will commence when construction is completed, and the facility is available for its intended use. The contractual construction commitment as of September 30, 2021, was \$6,610,568 (December 31, 2020 - \$7,084,300).

For the nine months ended September 30, 2021, depreciation expense was \$4,725,580 (2020- \$3,886,973) of which \$1,378,124 (2020 - \$1,167,206) was included in cost of goods sold.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

8) Licenses

	Retail Dispensary Santa Ana	Retail ispensary ark County	P	Cultivation and roduction ark County	Ma	Florida sterLicense	Total
Cost							
Balance at December 31, 2019	\$ -	\$ -	\$	-	\$	-	\$ -
Additions	5,607,564	690,000		709,798		-	7,007,362
Balance at December 31, 2020	\$ 5,607,564	\$ 690,000	\$	709,798	\$	-	\$ 7,007,362
Additions	-	-		-		258,060	258,060
Balance at September 30, 2021	\$ 5,607,564	\$ 690,000	\$	709,798	\$	258,060	\$ 7,265,422
Accumulated Depreciation							
Balance at December 31, 2020	\$ -	\$ -	\$	-	\$	-	\$ -
Amortization	-	-		-		-	-
Balance at September 30, 2021	\$ -	\$ -	\$	-	\$	-	\$ -
Net book value							
At December 31, 2020	\$ 5,607,564	\$ 690,000	\$	709,798	\$	-	\$ 7,007,362
At September 30, 2021	\$ 5,607,564	\$ 690,000	\$	709,798	\$	258,060	\$ 7,265,422

Santa Ana acquisition

On May 20, 2020, the Company closed on its acquisition of Newtonian Principles, Inc. resulting in the Company acquiring a California cannabis sales license held by Newtonian Principles, Inc and a 30-year lease for a dispensary in Santa Ana, California. The acquisition was accounted for as an asset purchase acquisition as Newtonian Principles, Inc. was deemed to not be a business under IFRS 3.

The following table summarizes the allocation of consideration exchanged to the estimated fair value of identifiable intangible assets acquired assumed:

Consideration paid:	
Cash	\$ 1,000,000
Issuance of 3,940,932 Class A shares (Note 14)	4,453,831
Transaction costs	 153,733
	\$ 5,607,564
Fair value of net assets acquired:	
Right of use asset	4,395,037
Right of use liability	(4,395,037)
Intangible asset license	\$ 5,607,564

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

8) Licenses (continued)

The license will be amortized over the remaining useful life of the Company's interest in the ROU assets of the property where the license is located.

WVapes acquisition

On July 17, 2020, the Company entered into an asset purchase agreement with West Coast Developments Nevada, LLC and W The Brand, LLC (together "WCDN") pursuant to which the Company acquired cannabis inventory, equipment and tenant improvements located in Las Vegas, Nevada. The acquisition was accounted for as an asset purchase acquisition as WCDN assets acquired was deemed to not be a business under IFRS 3.

The following table summarizes the allocation of consideration exchanged to the estimated fair value of tangible and intangible assets acquired:

Consideration paid:		
Cash	\$	1,656,667
Issuance of 1,374,833 common shares (Note 14)		2,918,277
Transaction costs		50,000
	\$	4,624,944
Fair value of assets acquired: Inventory Biological assets Fixed assets	\$	1,306,280 326,592 2,282,274
Intangible asset license	<u> </u>	709,798

The Company acquired two cultivation licenses (one medical and one recreational), two production licenses (one medical and one recreational) and one conditional distribution license. The transaction was scheduled to close in two parts, the first closing being cash transferred for the equipment and cannabis inventory which occurred on July 17, 2020, and the second closing (the "Second Closing") being contingent on the approval to transfer the license and receipt of the cultivation and production licenses from the State of Nevada's Cannabis Control Board ("CCB"). On August 25, 2020, the CCB conditionally approved the transfer of the cultivation and production licenses to MMDC, and on September 3, 2020, the Company received the cultivation and production licenses pursuant to a letter from the CCB.

By way of an October 10, 2020, letter from the CCB, the Company received a conditional distribution license from WCDN, which was later approved at a public hearing by the CCB on December 18, 2020.

On September 11, 2020, the Company mutually agreed with WCDN that the receipt by the Company of a business license issued by unincorporated Clark County which would permit the Company to conduct business in Clark County (the "Clark County Business License") was a necessary condition precedent to the Second Closing. As a result, the Second Closing occurred, and the 1,374,833 common shares in the Capital of the Company were released from escrow to WCDN, on November 27, 2020, upon receipt by the Company of the Clark County Business License.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

8) Licenses (continued)

Concurrent with the first closing of the WCDN assets acquired, RX Land, LLC ("RX Land"), an entity owned by the Corporation's co-CEOs, acquired the WCDN facility for US\$3.3 million and entered into a lease agreement with WCDN in respect of such facility (the "Initial West Bell Lease"). In accordance with the terms of the WCDN asset acquisition and approvals by the independent directors of Planet 13, WCDN assigned the Initial West Bell Lease to MMDC on November 25, 2020, and MMDC subsequently entered into an amending agreement with RX Land on November 27, 2020, to amend certain terms of such lease agreement including increasing the lease payments, extending the duration of the lease and, if desired, allowing for second floor installation by MMDC without a corresponding lease rate increase due to an increase in facility size. The entering into by MMDC of the assignment agreement and the amending agreement with RX Land constitutes a "related party transaction".

Medizin license acquisition

On July 31, 2020, the Nevada Tax Commission approved a settlement agreement between the Nevada Tax Commission, the Corporation and other plaintiffs, and intervening defendants (the "Nevada License Settlement") in connection with a lawsuit filed by the Company and other defendants after the defendants were notified in December 2018 that no licenses had been awarded to any of the defendants as part of a competitive application process that the Company and the other defendants had participated in for Nevada cannabis dispensary licenses in September 2018.

On August 7, 2020, the CCB convened and approved the Nevada License Settlement.

On September 3, 2020, the CCB transferred the conditional Clark County dispensary license to MMDC.

On November 20, 2020, the Corporation opened the Medizin store location, having received CCB final inspection approvals and a Clark County business license. The Company has capitalized \$690,000 in costs incurred to secure the license under the Nevada License Settlement.

Florida license acquisition and Restricted cash

On September 28, 2021, the Florida Department of Health's Office of Medical Marijuana Use ("OMMU") approved the Company to acquire license to operate as a Medical Marijuana Treatment Center issued by the Florida Department of Health from a subsidiary of Harvest Health & recreation Inc. As of September 30, 2021, the Company capitalized costs associated with the pending license acquisition in the amount of \$258,060 that had been incurred up to that date and had deposited \$55,000,000 in restricted cash with an escrow agent per the terms of the license acquisition agreement. The acquisition closed with an effective date of October 1, 2021, and the Company released \$55,000,000 of restricted cash that was being held in escrow to the seller in exchange for receipt of the Medical Marijuana Treatment Center license.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

9) Right of use Assets

	Buildings	Vehicles		Total
Cost				_
Balance at December 31, 2019	\$ 9,965,389	\$	148,736	\$10,114,125
Additions	11,457,392		-	11,457,392
Balance at December 31, 2020	\$ 21,422,781	\$	148,736	\$21,571,517
Additions	876,547		-	876,547
Disposals	(115,510)		(96,600)	(212,110)
Balance at September 30, 2021	\$ 22,183,818	\$	52,136	\$22,235,954
Accumulated Depreciation				
Balance at December 31, 2019	\$ 583,919	\$	51,473	\$ 635,392
Depreciation	734,931		51,473	786,404
Balance at December 31, 2020	\$ 1,318,850	\$	102,946	\$ 1,421,796
Depreciation	902,188		24,399	926,587
Disposals	(115,510)		(79,554)	(195,064)
Balance at September 30, 2021	\$ 2,105,528	\$	47,791	\$ 2,153,319
Net book value				
At December 31, 2020	\$ 20,103,931	\$	45,790	\$20,149,721
At September 30, 2021	\$ 20,078,290	\$	4,345	\$20,082,635

For the nine months ended September 30, 2021, depreciation expense was \$926,587 (2020-\$566,837) of which \$372,831 (2020 - \$182,757) was included in cost of goods sold.

10) Prepaid expenses and other current assets

	September 30,	December 31,
	2021	2020
Advertising and marketing	\$ 223,650	\$ 55,126
Security deposits	4,382,369	1,031,255
Taxes receivable/prepaid	409,554	37,163
Accounts receivable	831,158	436,874
Prepaid rent	325,366	205,177
D&O Insurance	378,894	153,076
Other insurance	208,870	397,870
Licenses	53,411	34,157
Miscellaneous	382,994	286,849
Total	\$ 7,196,266	\$ 2,637,547

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

11) Notes Payable

Notes payable consist of the following:

Non-related parties

	Sej	ptember 30, 2021	De	cember 31, 2020
Promissory note dated November 4, 2015, with semi-annual interest at 5.0%, secured by deed of trust, due December 1, 2019 Less current portion Long-term portion of Promissory Notes	\$	884,000 (884,000)	\$	884,000 (884,000)
Stated maturities of debt obligations are as follows: Next 12 months Promissory Note	\$	884,000	\$	884,000

The promissory note with an outstanding balance on September 30, 2021, and December 31, 2020, of \$884,000 is collateralized by a deed of trust on the related land.

12) Lease liabilities

The Company's lease agreements are for cultivation, manufacturing, retail and office premises and for vehicles. The property lease terms range between 7 years and 21 years depending on the facility and are subject to an average of 2 renewal periods of equal length as the original lease. Leases for vehicles are typically between 4 years and 6 years with no renewal terms. When measuring lease liabilities, the lease payments are discounted using the Company's weighted average incremental borrowing rate of 15%. The Company has only included extension options in the measurement of lease terms for those specific leases for which it is reasonably certain to exercise the related extension options.

	September 30,	December 31,
	2021	2020
Opening balance	\$ 22,326,077	\$ 10,522,377
Additions	876,547	9,174,693
Lease modifications	-	2,283,095
Interest and accretion	2,561,191	389,408
Principal payments	(2,469,078)	(167, 367)
Early lease termination	(23,065)	-
Prepaid rent	-	123,871
Ending balance	\$ 23,271,672	\$ 22,326,077
Less: current portion	86,700	
Long-term lease liabilities	\$ 23,184,972	\$ 22,326,077
	·	

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

12) Lease Liabilities (Continued)

The following table summarizes undiscounted future lease payments:

	September 30,	December 31,
	2021	2020
One year	\$ 3,573,514	\$ 3,237,879
Two years	3,706,604	3,363,263
Three years	3,845,841	3,493,363
Four years	3,964,293	3,626,543
Five years	3,881,211	3,704,263
Thereafter	47,083,499	49,857,920
Total undiscounted future lease payments	\$ 66,054,962	\$ 67,283,231
Effect of discounting	(42,783,290)	(44,957,154)
Present value of minimum lease payments	\$ 23,271,672	\$ 22,326,077

The following table summarizes lease-related cash flows for the nine months ended September 30, 2021, and the year ended December 31, 2020:

	September 30,	December 31,
	2021	2020
Principal and interest repayment	\$ 2,469,078	\$ 2,337,006
Non-lease components	280,154	324,988
Short-term leases	-	17,154
Total cash outflows	\$ 2,749,232	\$ 2,679,148
	•	

Non-lease components consist of payments for common area maintenance, utilities and property taxes and have not been considered in the calculation of the lease obligation. Short-term leases are leases with a lease term of 12 months or less. Payments associated with short-term leases are recognized as expenses on a straight-line basis.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital

a) Authorized

Unlimited number of common shares and unlimited number of Class A shares

Number of Shares		
	2021	2020
Common shares		
Balance at January 1	126,573,250	82,427,619
Shares issued on exercise of RSUs	915,803	2,685,344
Shares issued on exercise of options	121,336	333,001
Shares issued on exercise of warrants	3,758,940	17,532,271
Shares issued on financings	9,861,250	18,279,250
Shares issued on conversion of Class A shares	55,232,940	3,940,932
Shares issued on acquisition (Note 8)	-	1,374,833
Total Common shares outstanding September 30, 2021 and December 31, 2020	196,463,519	126,573,250
Class A shares		
Balance at January 1	55,232,940	55,232,940
Shares issued on acquisition (Note 8)	-	3,940,932
Conversion of Class A to Common	(55,232,940)	(3,940,932)
Total Class A Shares outstanding Septmber 30, 2021 and December 31, 2020	-	55,232,940
Balance September 30, 2021 and December 31, 2020	196,463,519	181,806,190

The Class A shares have equal rateable rights as the Company's common shares to dividends, all of the Company's assets that are available for distribution upon liquidation, dissolution or winding up of the Company's affairs, do not have preemptive rights, are entitled to receive notice and attend shareholders meetings and to exercise one vote for each Class A share held at all meetings of shareholders of the Company other than with respect to the vote for the election or removal of directors. Each Class A shareholder is able to convert each outstanding Class A share at the option of the holder thereof into one common share at any time provided that such conversion would not cause the Company to become a US Domestic Issuer. The restriction on conversion of Class A shares are designed to prevent the Company from becoming a US Domestic Issuer. Generally, a company will be considered to be a US Domestic Issuer if:

(A) 50% or more of the holders of a company's common voting shares are U.S. Persons; and either (B) (i) the majority of the executive officers or directors of the Issuer are United States citizens or residents; (ii) the company has 50% or more of its assets located in the United States; or (iii) the business of the company is principally administered in the United States.

On May 6, 2021, the Company issued 55,232,940 common shares on the conversion of 55,232,940 Class A shares. As of September 30, 2021, there were no longer any Class A shares outstanding.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital (continued)

As there are no restrictions on issue or transfer of the Company's common shares, there is no guarantee that the Company will not become a US Domestic Issuer in the future.

Nine Months ended September 30, 2021

On January 4, 2021, the Company issued 852,154 common shares on the exercise of Restricted Share Units ("RSUs") that had vested during the period.

On January 4, 2021, the Company issued 93,002 common shares on the exercise of options that had a strike price of CAD\$0.80 per common share resulting in cash proceeds of \$58,758 (CAD\$74,402).

On January 4, 2021, the Company issued 16,667 common shares on the exercise of options that had a strike price of CAD\$1.55 per common share resulting in cash proceeds of \$20,444 (CAD\$25,835).

On June 10, 2021, the Company issued 3,704 common shares on the exercise of Restricted Share Units that had vested during the period.

On July 9, 2021, the Company issued 59,945 common shares on the exercise of Restricted Share Units that had vested during the period.

On July 9, 2021, the Company issued 11,667 common shares on the exercise of options that had a strike price of CAD\$0.75 per common share resulting in cash proceeds of \$7,014 (CAD\$8,750)

During the nine months ended September 30, 2021, the Company issued 3,758,940 common shares to warrant holders who exercised 3,758,940 warrants resulting in cash proceeds of \$14,079,681 (CAD\$17,809,039),

Shares issued on Financings

On February 2, 2021, the Company completed a bought deal financing for aggregate gross proceeds of \$53,852,980 (CAD\$69,028,750) at a price of CAD\$7.00 per unit. The Company issued 9,861,250 units of the Company. Each unit was comprised of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of CAD\$9.00 per common share for a period of 24 months. The Company also issued 591,676 broker warrants that entitle the holder to purchase one common share for a period of 24 months from the closing of the offering at a price of CAD\$7.00 per common share. The broker warrants were measured based on the fair market value of the warrants using a Black Scholes valuation model as the fair market value of the services received cannot be reliably measured. The Company incurred \$3,496,448 in cash share issuance costs and allocated the net proceeds as follows: \$42,117,887 to the common shares that were issued, \$6,979,248 to the warrants that were issued and \$1,296,170 to the broker warrants that were issued for total net proceeds of \$50,393,305.

Year ended December 31, 2020

Shares issued for Stock Options and Restricted Share Units

During the year ended December 31, 2020, the Company issued 2,685,344 common shares on the exercise of RSUs that had vested during the period. The Company did not receive any cash proceeds on the exercise and transferred \$3,313,152 to share capital from the carrying value ascribed to the RSUs that were exercised.

On January 17, 2020, the Company issued 75,000 common shares on the exercise of options that had a strike price of CAD\$0.80 per common share resulting in cash proceeds of \$45,966 (CAD\$60,000).

On January 17, 2020, the Company issued 33,334 common shares on the exercise of options that had a strike price of CAD\$1.55 per common share resulting in cash proceeds of \$37,064 (CAD\$51,668).

On July 3, 2020, the Company issued 8,333 common shares on the exercise of options that had a strike price of CAD\$0.75 resulting in cash proceeds to the Company of \$4,617 (CAD\$6,249).

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital (continued)

On July 3, 2020, the Company issued 116,334 common shares on the exercise of options that had a strike price of CAD\$0.80 resulting in cash proceeds to the Company of \$68,771 (CAD\$93,066).

On October 9, 2020, the Company issued 50,000 common shares on the exercise of options that had a strike price of CAD\$0.80 resulting in cash proceeds to the Company of \$30,786 (CAD\$40,000).

On October 14, 2020, the Company issued 50,000 common shares on the exercise of options that had a strike price of CAD\$0.80 resulting in cash proceeds to the Company of \$30,786 (CAD\$40,000).

Shares issued on the exercise of Warrants

During the year ended December 31, 2020, the Company issued 17,532,271 common shares to warrant holders who exercised 17,532,271 warrants resulting in cash proceeds of \$32,653,449 (CAD\$43,079,021).

Shares issued for Acquisitions

On May 20, 2020, the Company issued 3,940,932 Class A restricted shares on the acquisition of Newtonian Principles Inc. (Note 9). The shares were valued at \$4,453,831 (CAD\$6,187,263, CAD\$1.57 per share based on the closing price of the Company's shares.)

On July 17, 2020, the Company issued 1,374,833 common shares on the acquisition of WCDN. The shares were valued at \$2,918,277 (CAD\$3,959,519, CAD\$2.88 per share based on the closing price of the Company's common shares on July 17, 2020) (Note 9).

Shares issued on Financings

On July 3, 2020, the Company completed a bought deal financing for aggregate gross proceeds of \$8,493,808 (CAD\$11,521,850) at a price of CAD\$2.15 per unit. The Company issued 5,359,000 units of the Company. Each unit was comprised of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of CAD\$2.85 per common share for a period of 24 months. The Company also issued 321,540 broker warrants that entitle the holder to purchase one common share for a period of 24 months from the closing of the offering at a price of CAD\$2.15 per common share. The broker warrants were measured based on the fair market value of the warrants using a Black Scholes valuation model as the fair market value of the services received cannot be reliably measured. The Company incurred \$825,359 in cash share issuance costs and allocated the net proceeds as follows: \$6,293,482 to the common shares that were issued, \$1,152,568 to the warrants that were issued and \$222,399 to the broker warrants that were issued for total net proceeds of \$7,668,449.

On September 10, 2020, the Company completed a bought deal financing for aggregate gross proceeds of \$17,489,401 (CAD\$23,019,550) at a price of CAD\$3.70 per unit. The Company issued 6,221,500 units of the Company. Each unit was comprised of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of CAD\$5.00 per common share for a period of 24 months. The Company also issued 373,290 broker warrants that entitle the holder to purchase one common share for a period of 24 months from the closing of the offering at a price of CAD\$3.70 per common share. The broker warrants were measured based on the fair market value of the warrants using a Black Scholes valuation model as the fair market value of the services received cannot be reliably measured. The Company incurred \$1,291,216 in cash share issuance costs and allocated the net proceeds as follows: \$12,645,312 to the common shares that were issued, \$2,967,057 to the warrants that were issued and \$585,816 to the broker warrants that were issued for total net proceeds of \$16,198,185.

On November 5, 2020, the Company completed a bought deal financing for aggregate gross proceeds of \$22,141,920 (CAD\$28,804,625) at a price of CAD\$4.30 per unit. The Company issued 6,698,750 units of the Company. Each unit was comprised of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of CAD\$5.80 per common share

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital (continued)

for a period of 24 months. The Company also issued 401,925 broker warrants that entitle the holder to purchase one common share for a period of 24 months from the closing of the offering at a price of CAD\$4.30 per common share. The broker warrants were measured based on the fair market value of the warrants using a Black Scholes valuation model as the fair market value of the services received cannot be reliably measured. The Company incurred \$1,544,014 in cash share issuance costs and allocated the net proceeds as follows: \$16,126,056 to the common shares that were issued,

\$3,741,328 to the warrants that were issued and \$730,522 to the broker warrants that were issued for total net proceeds of \$20,597,906.

b) Stock options

The Company has established an incentive stock option plan (the "Plan") for employees, management, directors, and consultants of the Company, as designated and administered by a committee of the Company's Board of Directors. Under the Plan, the Company may grant options for up to 10% of the issued and outstanding common shares of the Company.

Nine months ended September 30, 2021

No incentive stock options were granted during the period.

During the year ended December 31, 2020

No incentive stock options were granted during the year.

The following table summarizes information about stock options outstanding as at September 30, 2021, and December 31, 2020:

	Exercise	September-30	September-30	December 31,	December 31,
	Price	2021	2021	2020	2020
Expiry date	CAD\$	Outstanding	Exercisable	Outstanding	Exercisable
June 11, 2023	\$0.80	61,668	61,668	158,004	158,004
July 31, 2023	\$0.75	-	-	11,667	11,667
January 7, 2024	\$1.55	-	-	16,667	-
June 30, 2024	\$2.60	7,500	7,500	7,500	-
July 4, 2022	\$2.65	100,000	100,000	100,000	100,000
		169,168	169,168	293,838	269,671

The employee options vest one third on the grant date and one third on the first and second anniversary of the grant date.

Share based compensation expense attributable to employee options that vested during the nine months ended September 30, 2021, was \$3,104 (\$51,233 for the nine months ended September 30, 2020).

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital (Continued)

The following table reflects the continuity of stock options for the periods presented:

	September 30,	Weighted	December 31,	Weighted
	2021	Average CAD\$	2020	Average CAD\$
Stock option activity		Exercise price		Exercise price
Balance – beginning of year	293,838	\$1.52	666,842	\$1.22
Granted	-	-	-	-
Exercised	(121,336)	\$0.91	(333,001)	\$0.87
Expired	(3,334)	\$0.80	(40,003)	\$1.79
Forfeited	-	-	-	
Balance – end of period	169,168	\$1.97	293,838	\$1.52

	September 30,	December 31,
	2021	2020
The outstanding options have a weighted-average CAD\$ exercise price of:	\$1.97	\$1.52
The weighted average remaining life in years of the outstanding options is:	1.19	2.19

c) Warrants

The following table summarizes warrants outstanding at September 30, 2021:

		CAD\$	September 30,	December 31,
		Exercise	2020	2020
Date of Issuance	Date of Expiry	Price	Outstanding	Outstanding
December 4, 2018	January 28, 2021	\$3.75	-	1,101,211
July 3, 2020	July 3, 2022	\$2.85	363,388	591,488
September 10, 2020	September 10, 2022	\$5.00	378,659	2,065,400
November 5, 2020	November 5, 2022	\$5.80	2,927,141	3,249,275
November 5, 2020	November 5, 2022	\$4.30	-	150,963
February 2, 2021	February 2, 2023	\$9.00	4,910,625	-
February 2, 2021	February 2, 2023	\$7.00	295,838	-
			8,875,651	7,158,337

	September 30,	December 31,
	2021	2020
The outstanding warrants have a weighted-average CAD\$ exercise price of:	\$7.46	\$4.98
The weighted average remaining life in years of the outstanding warrants is:	1.22	1.63

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital (continued)

The following table reflects the continuity of warrants for the periods presented:

	September 30,	Weighted	December 31,	Weighted
	2021	Average CAD\$	2020	Average CAD\$
Warrant activity	Number	Exercise price	Number	Exercise price
Balance - beginning of the period	7,158,337	\$4.98	15,061,078	\$2.20
Issued	5,522,301	\$8.79	10,236,380	\$4.53
Exercised	(3,758,940)	\$4.74	(17,532,271)	\$2.46
Expired	(46,047)	\$3.75	(606,850)	\$1.40
Balance – end of the period	8,875,651	\$7.46	7,158,337	\$4.98

The Company received cash proceeds of \$14,079,681 from the exercise of warrants during the nine months ended September 30, 2021. The Company reduced the carrying value of warrants by \$3,761,366 that was associated with the warrants that were exercised and reallocated this amount to common share capital.

The Company received cash proceeds of \$32,653,449 from the exercise of warrants during the year ended December 31, 2020. The Company reduced the carrying value of warrants by \$8,388,728 that was associated with the warrants that were exercised and reallocated this amount to common share capital.

The following assumptions were used to arrive at the value ascribed to the Warrants issued using a Black Scholes Option Pricing model:

Assumption	February 2, 2021	February 2, 2021	November 5, 2020	November 5, 2020	September 10, 2020	September 10, 2020	July 3, 2020	July 3, 2020
Share price - CAD\$	\$6.80	\$6.80	\$4.89	\$4.89	\$4.13	\$4.13	\$2.04	\$2.04
Strike price	\$9.00	\$7.00	\$5.80	\$4.30	\$5.00	\$3.70	\$2.85	\$2.15
Risk-free rate	0.16%	0.16%	0.25%	0.25%	0.26%	0.26%	0.29%	0.29%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Expected volatility	78.30%	78.30%	84.20%	84.20%	88.70%	88.70%	89.30%	89.30%
Warrant life in years	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Acceleration Threshold	None	None	None	None	None	None	None	None

d) Restricted Share Units

The Company has established a Restricted Share Unit incentive plan (the "RSU Plan") for employees, management, directors, and consultants of the Company, as designated and administered by a committee of the Company's Board of Directors. Under the RSU Plan, the Company may grant RSUs and/or options for up to 10% of the issued and outstanding common shares of the Company.

During the nine months ended September 30, 2021

On January 4, 2021, the Company issued 852,154 common shares on the vesting of 852,154 RSUs that were outstanding. The Company did not receive any cash proceeds from the issuance.

On April 19, 2021, the Company granted 4,082,474 RSUs to officers, directors, and employees pursuant to the Company's RSU Plan. The RSUs granted vest in three equal tranches on November 1, 2021, November 1, 2022, and November 1, 2023, unless otherwise varied pursuant to the terms of the plan.

On June 10, 2021, the Company granted 3,704 RSUs to a consultant of the Company. Pursuant to the Company's RSU Plan. The RSUs vested immediately and were exercised on June 10, 2021. The company issued 3,704 common shares on the exercise and did not receive any cash proceeds from the issuance.

In total the Company transferred \$1,898,979 to share capital from Restricted Share Units, representing the carrying value of the RSUs that were exercised during the period.

During the year ended December 31, 2020

On January 1, 2020, the Company issued 50,000 RSUs under the RSU plan. The value ascribed to the RSUs issued was CAD\$2.57 per share, the closing share price of the Company's common shares on December 31, 2019.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

13) Share Capital (continued)

On June 30, 2020, 6,666 RSUs that were previously granted on June 11, 2018, were cancelled as a result of an employee resignation.

On July 3, 2020, the Company issued 50,518 RSUs under the RSU plan. The value ascribed to the RSUs issued was CAD\$2.04 per share, the closing share price of the Company's common shares on July 3, 2020.

The following table summarizes the RSUs that are outstanding as at September 30, 2021:

Restricted Share Units (RSUs)		September 30,	September 30,	December 31,	December 31,
	Share Price	2021	2021	2020	2020
Grant Date	on Grant Date	Outstanding	Vested	Outstanding	Vested
June 30, 2019	CAD\$2.60	835,485		1,730,917	-
January 1, 2020	CAD\$2.52	16,666	-	33,333	-
April 19, 2021	CAD\$8.12	4,082,474	-	-	-
June 10, 2021	CAD\$8.51	-	-	-	-
		4,934,625	_	1,764,250	-

	September 30,	December 31,
	2021	2020
RSU Activity		
Balance – beginning of the period	1,764,250	4,355,742
Granted to participants	4,086,178	100,518
Exercised	(915,803)	(2,685,344)
Cancelled	-	(6,666)
Balance – end of the period	4,934,625	1,764,250

The Company recognized \$12,208,463 in share-based compensation expense attributable to RSUs vesting during the nine months ended September 30, 2021(\$1,954,834 for the nine months ended September 30, 2020).

14) General and Administrative Expenses

		For the nine months ended			
Septen	nber, 30	September, 30			
2021	2020	2021	2020		
\$ 6,134,539	\$ 2,420,126	\$ 14,481,158	\$ 6,546,241		
447,800	392,142	1,385,009	897,203		
969,610	301,707	2,258,551	1,296,695		
931,950	451,497	2,380,171	1,370,969		
621,642	275,107	1,562,832	641,796		
953,356	444,175	2,166,299	1,056,499		
938,028	848,726	2,842,599	2,592,331		
2,114,724	1,064,641	4,735,647	2,878,524		
\$ 13,111,649	\$ 6,198,121	\$ 31,812,266	\$ 17,280,258		
	Septen 2021 \$ 6,134,539 447,800 969,610 931,950 621,642 953,356 938,028 2,114,724	\$ 6,134,539 \$ 2,420,126 447,800 392,142 969,610 301,707 931,950 451,497 621,642 275,107 953,356 444,175 938,028 848,726 2,114,724 1,064,641	September, 30 September 2021 2020 2021 \$ 6,134,539 \$ 2,420,126 \$ 14,481,158 447,800 392,142 1,385,009 969,610 301,707 2,258,551 931,950 451,497 2,380,171 621,642 275,107 1,562,832 953,356 444,175 2,166,299 938,028 848,726 2,842,599 2,114,724 1,064,641 4,735,647		

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

15) Commitments and Contingencies

(a) Construction Commitments

At September 30, 2021, the Company had construction commitments outstanding of \$6,610,568 (December 31, 2020 - \$7,084,300), \$2,904,562 related to the build-out of the Company's Planet 13 Santa Ana cannabis entertainment complex and \$3,706,006 related to the build out of the Company's Planet 13 Las Vegas Superstore.

(b) Contingencies

The Company's operations are subject to a variety of local and state regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as at September 30, 2021, medical and adult use cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties, or restrictions in the future.

(c) Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At September 30, 2021, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's operations. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

(d) Operating Licenses

Although the possession, cultivation, and distribution of marijuana for medical and adult use is permitted in Nevada and California marijuana is a Schedule-I controlled substance and its use remains a violation of federal law. Since federal law criminalizing the use of marijuana pre-empts state laws that legalize its use, strict enforcement of federal law regarding marijuana would likely result in the Company's inability to proceed with our business plans. In addition, the Company's assets, including real property, cash, equipment and other goods, could be subject to asset forfeiture because marijuana is still federally illegal.

(e) Employment Agreements

The Company has employment agreements in place with its Executive Management team and certain key employees. The annual salaries pursuant to such agreements range from \$100,000 to \$500,000.

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

16) Basic and Diluted Net Loss per share

	Nine Mon	ths Ended
-	September 30,	September 30,
	2021	2020
Basic weighted average shares outstanding		
Common shares	196,357,392	87,786,213
Restricted voting shares	-	57,145,874
Total Basic and diluted weighted average shares outst	196,357,392	144,932,087
Effect of dilutive securities		
Net incremental shares from conversions of:		
Options	-	-
Warrants	-	-
RSUs	-	-
Diluted weighted average shares outstanding	196,357,392	144,932,087
Net loss for the period	\$ (12,400,121)	\$ (5,036,208)
Basic loss per share	\$ (0.06)	\$ (0.03)
Fully diluted loss per share	\$ (0.06)	\$ (0.03)
,	(0.00)	- (0.00

17) Related party transactions

Related party transactions are summarized as follows:

(a) Officer Compensation

The Company's key management personnel have the authority and responsibility for planning, directing and controlling the activities of the Company and consists of the Company's executive management team and board of directors. The following table summarizes amounts paid to related parties as compensation for the nine months ended September 30, 2021, and 2020:

	Nine Months ended		emuneration	Share based Included in accounts			
	September 30,		or fees (1)		payments (1)		payable (1)
Management compensation	2021	\$	1,945,223	\$	9,875,693	\$	-
	2020		1,194,466		1,404,237		8,176
Director compensation	2021 2020	\$	150,000	\$	1,227,580 199,254	\$	-

⁽¹⁾ Amounts disclosed were paid or accrued to the related party during the nine months ended September 30, 2021 and 2020.

(b) Other

The Company sub-lets approximately 2,000 square feet of office space and purchases certain printed marketing collateral and stationery items from a company owned by one of the Company's Co-CEOs. Amounts paid to such company for rent for the nine months ended September 30, 2021, and 2020 equaled \$16,027 and \$18,030, respectively. Amounts paid for printed marketing collateral and stationery items equaled \$382,264 and \$215,069 respectively for the nine months ended September 30, 2021, and 2020. As at September 30, 2021, there was \$22,682 (2020-\$61,407) included in accounts payable that was owed to this related party.

A company owned by one of the Company's executives pays the Company for storage space. Amounts paid to the Company for storage space equaled \$122,447 for the nine months ended September 30, 2021 (2020 – nil).

NOTES TO THE UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021, AND 2020

Expressed in United States Dollars, unless otherwise indicated

17) Related party transactions (continued)

Through to April 30, 2021, the Company leased a cultivation facility from an entity owned by the Company's co-CEOs. Rents paid for this facility for the nine months ended September 30, 2021, equaled \$301,894 (2020 – nil). On April 30, 2021, the Company's Co-CEOs sold this building to an arm's length third party who assumed the lease.

18) Segmented disclosure

a) Operating segments

The Company operates in a single reportable operating segment as a vertically integrated cannabis company with cultivation, production and distribution operations in the state of Nevada and retail distribution in Santa Ana California.

b) Geographic segments

As at September 30, 2021, and December 31, 2020, all the Company's non-current assets were located in the United States.

19) Capital Management

The Company's capital structure consists of all components of shareholders' equity, leases and notes payable. The Company's objective when managing capital is to maintain adequate levels of funding to support the day-to-day business activities of its cannabis operations in Nevada as well as to fund strategic initiatives, including the buildout of phase II of the Superstore Cannabis Entertainment Complex as well as to fund future expansion opportunities in other locations that may arise and maintain the necessary corporate and administrative functions to facilitate these activities. This has been done primarily through equity financing. Future equity financings are dependent on market conditions and there can be no assurance the Company will be able to raise funds in the future.

The Company invests all capital that is surplus to its immediate operational needs in short-term, highly-liquid, high-grade financial instruments. There were no changes to the Company's approach to capital management during the nine months ended September 30, 2021, or the year ended December 31, 2020. The Company is not subject to externally imposed capital requirements.

20) Subsequent Event

On October 1, 2021, the Company completed the purchase of a license issued by the Florida Department of Health to operate as a Medical Marijuana treatment Center (the "License") in the state of Florida for \$55,000,000 in cash (Note 8).